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Background and aim: Assessing cranial artery inflammation plays an important role in the diagnosis of cranial
giant cell arteritis (C-GCA). However, current diagnostic tests are limited. The use of fluorine-18-fluorodeoxy-
glucose (FDG) positron emission tomography (PET)/CT imaging is an established tool for assessing large ves-
sel inflammation but is currently not used for assessment of the cranial arteries. This study aimed to evaluate
the accuracy of FDG-PET/CT in the diagnosis of biopsy proven C-GCA and its relation to clinical presentation.
Methods: This retrospective case control study included temporal artery biopsy (TAB) positive C-GCA patients
and age- and sex-matched controls. FDG-PET/CT scans were performed according to EANM/EARL guidelines,
visually assessed by an experienced nuclear medicine physician, and semiquantitatively assessed using the
maximum standardised uptake value (SUVmax). The visual and semiquantitative assessments were per-
formed on the temporal arteries, maxillary arteries, vertebral arteries, and occipital arteries. Clinical signs
and symptoms were scored for comparison.
Results: A total of 24 C-GCA patients and 24 controls were included in the study. Visual analysis revealed an
83% sensitivity and a 75% specificity. Receiver operating characteristic (ROC) analysis of the semiquantitative
assessment revealed a 79% sensitivity and a 92% specificity when measuring SUVmax in the cranial arteries.
Visual and semiquantitative assessments showed moderate agreement (Fleiss kappa 0.55). There was a posi-
tive correlation between the number of cranial symptoms and the SUVmax in the vertebral artery.
Conclusion: FDG-PET/CT can reliably diagnose C-GCA by assessing cranial artery inflammation using SUVmax.
Extending the use of FDG-PET/CT to include assessment of the cranial arteries may improve its diagnostic
value in GCA and provide a suitable alternative to TAB. Moderate agreement between visual and semiquanti-
tative assessment methods suggest diagnostic accuracy may be improved by further standardisation.
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Giant cell arteritis (GCA) is a large vessel vasculitis most com-
monly affecting the aorta and its major branches. Within the GCA
spectrum, different patterns of vessel involvement may be recognised
[1]. In cranial GCA (C-GCA), the arteries of the head and the neck,
such as the temporal, maxillary, and vertebral arteries are affected. Inlarge vessel GCA (LV-GCA), arteries such as the aorta and subclavian
arteries may be involved. Approximately 70% of patients present
with an overlap of these two disease patterns. Nonetheless, C-GCA
and LV-GCA differ in their clinical presentation, complications, diag-
nostic approach, and may also have a different outcome [2].
The clinical presentation of C-GCA includes new-onset head-
ache often characterized by a burning sensation on the scalp, jaw
claudication and an enlarged painful temporal artery upon palpa-
tion. Importantly, visual manifestations due to ischaemia of the
optic nerve are common in C-GCA [3]. These manifestations may
be intermittent at the outset but can lead to irreversible vision
loss if left untreated [4]. Other medical emergencies associated
with C-GCA are transient ischaemic attacks (TIA) and cerebrovas-
cular accidents (CVA). The clinical presentation of LV-GCA
includes claudication of the extremities, discrepancy in blood
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Constitutional symptoms such as fever, malaise, and weight loss
present equally in both disease variants [5].
The risk of ischaemic complications stresses the need for fast diag-
nosis of C-GCA [3]. Temporal artery biopsy (TAB) has long been con-
sidered as the gold standard for diagnosing GCA. Because of its high
specificity, TAB can confirm a C-GCA diagnosis with a high level of
certainty. However, TAB has a low sensitivity and a high interob-
server variability between pathologists has been reported [6]. Addi-
tionally, treatment is often started before the TAB results are
available and is also rarely altered after a negative TAB result [7].
The European League Against Rheumatism (EULAR) recommends
that after careful clinical examination, imaging is the preferred first
diagnostic test [8]. Duplex ultrasonography (US) of the axillary and
temporal arteries has a 54% sensitivity and an 81% specificity, and
highly depends on the skill of the examiner and the US machine [6].
Magnetic resonance imaging (MRI) can also be used in C-GCA by
assessing the temporal and occipital arteries, resulting in a sensitivity
of 93% and a specificity of 88% [9]. Limiting factors of MRI are long
waiting times and its unknown use in LV-GCA.
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET)/CT is an imaging test routinely used in GCA patients to
detect large artery involvement. Due to their high metabolic activity,
inflammatory cells such as macrophages and lymphocytes show high
uptake of FDG [10]. The recommended way of analysing FDG uptake
in the arteries is by visual assessment. Additionally, semiquantitative
measurements of FDG uptake, such as the standardised uptake value
(SUV), are regularly used in research and may offer a more objective
measure of inflammation [11].
The recommended use of FDG-PET/CT in GCA is currently limited
to detect extracranial vascular involvement. Its use in the diagnosis
of C-GCA is currently not recommended, but the potential application
of FDG-PET/CT in C-GCA should be evaluated [8,11]. Assessment of
the cranial arteries has historically been difficult due to the high
physiological FDG uptake in the brain. In 2004, a study deemed FDG-
PET unsuitable to detect GCA in arteries with a diameter smaller than
4 mm, therefore excluding most cranial arteries [12].
Using newer generation PET/CT scanners and new reconstruction
methods, recent studies show high diagnostic accuracy when using
FDG-PET/CT for detecting cranial artery involvement in GCA [13,14].
These studies however included only visual assessment of cranial
artery inflammation, which is prone to subjectivity. Additionally, no
study yet investigated the link between the clinical signs of cranial
artery inflammation and FDG uptake in the cranial arteries.
The current study aimed to evaluate the diagnostic accuracy of
FDG-PET/CT in TAB positive C-GCA patients, using both visual and
semiquantitative methods. Additionally, results of the assessments
were compared with the clinical presentation of the patient.
Methods
This retrospective case-control study was performed at the
departments of Rheumatology and Clinical Immunology and Nuclear
Medicine and Molecular Imaging of the University Medical Center
Groningen (UMCG), the Netherlands. Data were collected from the
hospital’s pathology database, health record system, and radiology
servers. The study was approved by the Medical Ethics Review Board
(METc) of the UMCG (METc number 2018/472).
Cases
Reports of TABs performed between 2008 and 2018 were obtained
from the pathology database. Positive TABs were selected and the hos-
pital health record system was subsequently checked for FDG-PET/CT
scans. Demographic data, signs and symptoms, and relevant medical
history were also retrieved from the health record system.Patients were excluded if they were concurrently diagnosed with
malignancies or autoimmune diseases. Glucocorticoid therapy nota-
bly decreases the FDG-PET/CT signal 3 days after commencing ther-
apy [15]. Therefore, patients receiving glucocorticoid therapy were
excluded if the treatment duration exceeded 3 days at the time of
FDG-PET/CT.
Controls
Follow up scans of patients diagnosed with melanoma without
evidence of disease on FDG-PET/CT were chosen as controls. Scans
were performed between 2013 and 2018. Patients treated for a mela-
noma at time of imaging were excluded. Additionally, patients who
underwent surgery in the six months prior to the FDG-PET/CT scan
were excluded. Patients diagnosed with other malignancies or auto-
inflammatory diseases were also excluded. Controls were matched
for age (§ 3 years) and sex (1:1).
Assessment of clinical presentation
Signs and symptoms from physician reports closest before the
date of FDG-PET/CT were collected from the electronic health record
system. The data collected on cranial symptoms were the presence of
new or different headache, scalp tenderness, temporal artery tender-
ness, ischaemia-related vision loss, jaw claudication, and the occur-
rence of a transient ischaemic attack (TIA) or a cerebrovascular
accident (CVA). The data collected on the systemic symptoms were
the presence of fever, weight loss, malaise, night sweats, arm claudi-
cation, and leg claudication.
FDG-PET/CT scanning procedure
All FDG-PET/CT scans of GCA patient cases and melanoma patient
controls were performed on a Biograph mCT camera system (Siemens
Medical Systems, Knoxville, TN). Patients were instructed to fast
6 hours prior to intravenous injection of 3 MBq/kg of FDG. Imaging
commenced 60 minutes after injection and scanned either from head
to proximal femur or from head to feet. The number of minutes per
bed position was adjusted to the body weight of the patient. Since
2017, patients suspected of vasculitis had their head scanned for 5
minutes per bed position, which in our study concerns 7 out of 24
cases. Consequently, this constitutes a minor difference in scanning
procedures between cases and controls in this study.
The PET image reconstruction method was selected by optimising
reconstruction settings in order to best visualise the cranial arteries.
Using iterative reconstruction, optimisation was performed by apply-
ing variable number of iterations and types of postreconstruction fil-
ters. PET reconstruction optimisation was based on expertise of a
clinical physicist and chosen by an experienced nuclear medicine
physician. The resulting PET reconstruction parameters comprised 4
iterations and 21 subsets. Reconstruction did not involve postrecon-
struction filtering, hereby deviating from standard protocols [16].
Additionally, reconstruction employed point-spread function (PSF),
time of flight (TOF), and a matrix size of 512 £ 512. Attenuation cor-
rection was also used. Imaging artefacts produced by (dental) pros-
theses as a result of attenuation correction were occasionally present
but did not interfere when assessing the cranial arteries.
FDG-PET/CT assessment
Both visual assessment and semiquantitative assessments were
performed using Syngo.Via software (version VB20A_HF05) (Siemens
Healthcare, Erlangen, Germany). The temporal arteries (TA), maxil-
lary arteries (MA), vertebral arteries (VA), and occipital arteries (OA)
were scored bilaterally. All scans were anonymised and scored
blinded for any clinical data.
Table 1
US, ultrasound; FDG-PET/CT, Fluorine-18-fluorodeoxyglucose-Positron Emis-
sion Tomography/Computed Tomography; CI, confidence interval; TIA, tran-
sient ischaemic attack; CVA, cerebrovascular accident; SD, standard
deviation; CPR, c-reactive protein; TAB, temporal artery biopsy; GC, gluco-
corticoid; IQR, interquartile range.
Number of patients 24
Demographics
Female gender 12 (50%)
Age, years [mean (SD)] 71 (8)
Symptoms
Cranial symptoms 21 (88%)
New or different headache 18 (75%)
Scalp tenderness 8 (33%)
Temporal artery tenderness 5 (21%)
Jaw claudication 7 (29%)
TIA/CVA 2 (8%)
Constitutional symptoms 19 (80%)
Fever 6 (25%)
Weight loss 13 (54%)
Night sweats 12 (50%)
Arm claudication 2 (8%)
Leg claudication 4 (17%)
Diagnostics
Serum CRP, mg/L [median (95% CI)] 73 (37-110)
Temporal artery biopsy 24 (100%)
Adventitial pattern 3 (13%)
Adventitial invasive pattern 3 (13%)
Concentric bilayer pattern 1 (4%)
Panarteritic pattern 17 (71%)
Duplex Ultrasound 15 (63%)
Positive Duplex ultrasound 9 (60%)*
FDG-PET/CT
Number of patients concurrently on GC treatment 3
Serum glucose, mmol/L [median (IQR)] 6.1 (5.7-6.8*)
Days since treatment initiation [median (range)] 2 (1-3)
Number of days from PET/CT to TAB [median (IQR)] 4 (-1-9**)
Patients with LV involvement on FDG-PET/CT 15
* the GCA group included three patients whose serum glucose levels
exceeded 7 mmol/L.
**the GCA group included two patients who had TAB performed 2 and 6 years
prior to the FDGPET/CT scan. FDG-PET/CT was performed because of a sus-
pected clinical recurrence. In both cases, FDG-PET/CT confirmed active LV-
GCA
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Visual assessment was performed by an experienced nuclear
medicine physician. As described in a previous study, visual assess-
ment was rated on a 0-2 scale [13]. Uptake was scored as ‘0’ when
there is no visible uptake higher than surrounding tissue, scored ‘1’
when uptake is slightly higher than surrounding tissue, and scored
‘2’when uptake is significantly higher than surrounding tissue.
Semiquantitative assessment
Semiquantitative scoring was performed by measuring SUV
within a volume of interest (VOI). Using the 3D-isocontour tools,
spherical VOIs were drawn around the anatomical locations of the
relevant cranial arteries. The SUVmax in every mentioned cranial
artery of each case was recorded. Additionally, the highest measured
SUVmax in the lumen of the superior caval vein (SCV) was also
included as background blood pool activity, in order to calculate a
target-to background ratio (TBR) to correct for possible variance in
systemic uptake between patients [11].
Statistical analysis
Fisher’s exact test was used to assess differences in visual assess-
ment and quantitative assessment cross-tabulations. Fisher’s exact
test was also used to compare between the cranial artery assessment
with the categorised clinical data. Mann-Whitney-U test was per-
formed to test the differences between two groups of the quantitative
assessment data, and the Kruskall-Wallis test was used to compare
multiple groups. Receiver operating characteristics (ROC) analysis
was used to determine the diagnostic value and to diagnostic cut-off
values of the quantitative assessment. The area under the curve
(AUC) of the ROC curve was used to compare between subgroups.
Cohen’s kappa (k) was used to assess agreement between the visual
and quantitative assessment methods, where a k<0 was considered
poor agreement, k=0-0.20 fair agreement, k=0.41-0.60 moderate
agreement, k=0.61-0.80 substantial agreement, and k>0.81 almost
perfect agreement, based on the Fleiss criteria (Fleiss DL, Statistical
methods for rates and proportions. 2nd ed New York: 1981:212-
236.). To calculate the correlations of the quantitative assessment
and scored clinical presentation, Spearman’s correlation coefficient
was used. P-values less than 0.05 are considered statistically signifi-
cant. All statistical analyses and graphs were made using GraphPad
Prism software (version 8.0, GraphPad Software, Inc., CA).
Results
In total, 24 TAB positive C-GCA patients and 24 matched disease-
free melanoma controls were included in the study. Baseline charac-
teristics of the C-GCA patients are shown in Table 1. The median serum
glucose level in the control group was 5.3 mmol/L (IQR 5.0-5.6) com-
pared to 6.1 mmol/L (IQR 5.7-6.8) in the C-GCA group (p<0,001).
Overall, the intensity and distribution of FDG uptake in the cranial
arteries differed between GCA patients and controls. High intensity
uptake on visual assessment (visual score  1, see Fig. 1) and high SUV-
max were found predominantly in C-GCA patients. The highest SUVmax
across all arterial regions are plotted in Fig. 2. High intensity FDG uptake
in C-GCA patients was predominantly found in the TA, MA, and VA. In
the control group, SUVmax did not differ between left sided and right
sided arteries. In the C-GCA group, highest and lowest median SUVmax
values were observed in respectively the VA and OA. The mean SUVmax
value of the SCV was comparable in the C-GCA and control groups.
Performance of visual assessment of cranial artery inflammation
Visually scored FDG uptake above surrounding tissue (visual score
 1) resulted in an 83% sensitivity and 75% specificity for diagnosing
C-GCA. When only high intensity uptake (visual score = 2) wasconsidered, sensitivity decreased to 58% and increased specificity to
96%. Fig. 1 shows example images of the visual scoring assessment.
Cross tabulation for visual assessment results are shown in Table 2
and shows that higher FDG uptake most frequently involves the TA
and least frequently involves the OA. Out of the 24 biopsied TAs, 14
were regarded positive (visual score  1) on visual assessment. In 5
patients showing no FDG uptake in the biopsied TAs, there was
involvement of other cranial arteries. Additionally, 9 patients show-
ing TA FDG uptake also showed involvement in other arteries. On
visual assessment 9 patients showed bilateral TA involvement and 3
showed unilateral involvement of the non-biopsied TA. Further anal-
ysis showed that in 13 of the 24 C-GCA cases, multiple distinct arte-
rial regions were affected, whereas the control group only had single
positive arterial regions.Performance of semiquantitative assessment of cranial artery
inflammation
A ROC analysis of the highest measured SUVmax in both GCA and
control cases revealed an area under the curve (AUC) of 0.88
(CI95%=0.77-0.99), attributing to a 79% sensitivity and a 92% specificity
for a cut-off SUVmax of 5.00 (Fig. 3). ROC analysis of target-to-back-
ground ratio of the cranial arteries SUVmax divided by the SVC SUV-
max resulted in an AUC of 0.84.
The image below in Fig. 3 shows sub-analysis ROC curves for the
cranial arteries. Highest AUC was attained by the VA and the lowest by
the OA. Table 3 shows a cross-tabulation of the results of
Fig. 1. Visual assessment of cranial artery inflammation on FDG-PET/CT. Temporal Artery (TA), Maxillary Artery (MA), Vertebral Artery (VA), and Occipital Artery (OA) were bilater-
ally visually scored from 0-2. Scoring definition: 0: no uptake above surrounding tissue; 1: uptake just above surrounding tissue; 2: uptake significantly above surrounding tissue.
The red circle denotes the visually determined area of increased uptake.
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5.00, showing the VA was most affected. Out of the 24 biopsy-positive
TA, 9 had a SUVmax higher than 5.00 on semiquantitative assessment.
In 10 patients showing no involvement of the biopsied TAs, there was
involvement of other cranial arteries. Additionally, 8 patients showing
involvement in the biopsied TAs also showed involvement in other
arteries. Bilateral TA involvement was present in 2 cases and 2 others
showed unilateral involvement of the non-biopsied TA. Furthermore,
in 12 out of 24 of the cases, the SUVmax was higher than 5.00 in more
than one arterial region, whereas positive controls each presented a
SUVmax higher than 5.00 in only one arterial region.Association of cranial artery assessment and large vessel assessment
Out of the 24 C-GCA patients, 15 showed large artery involvement
on FDG-PET/CT. Six patients showed only cranial artery involvement.
In three patients, there was neither large artery nor cranial artery
involvement on FDG-PET/CT.
Comparison of visual and semiquantitative FDG-PET/CT assessments
In 37 (77%) out of all 48 subjects, the visual and semiquantitative
method agreed on the presence of cranial artery uptake, defined as
Fig. 2. Data of measured SUVmax values of each vessel in boxplots. Each box represents the 25th to 75th percentiles, outliers (>1.5£ Q1,Q3) are represented as dots. Results Mann-
Whitney U: ns, p>0.05; * p0.05; ** p0.01; *** p0.001; **** p0.0001. SCV, superior caval vein; RTA, right temporal artery; LTA, left temporal artery; RMA, right maxillary artery;
LMA, left maxillary artery; RVA, right vertebral artery; LVA, left vertebral artery; ROA, right occipital artery; LOA, left occipital artery; MAX, highest SUVmax in the assessed cranial
arteries.
Table 2
Cross tabulation of the results of visual assessment of FDG uptake in the cranial arteries. Results for bilat-
erally assessed cranial arteries, combinations of cranial arteries, and sensitivity and specificity are shown.
TA, temporal artery; MA, maxillary artery; VA, vertebral artery; OA, occipital artery; CI95%, 95% confi-
dence interval.
Cranial Artery: Visual Assessment GCA Control Sensitivity (CI95%) Specificity (CI95%)
TA/MA/VA/OA Positive 20 6 83% (64-93) 75% (55-88)
Negative 4 18
TA Positive 18 2 75% (55-88) 92% (74-99)
Negative 6 22
MA Positive 12 1 50% (31-69) 96% (80-100)
Negative 12 21
VA Positive 10 0 41% (24-61) 100% (86-100)
Negative 14 24
OA Positive 7 2 29% (15-49) 92% (74-99)
Negative 17 22
MA/VA/OA Positive 15 4 63% (43-79) 83% (64-93)
Negative 9 20
TA/MA/VA Positive 20 4 83% (64-93) 83% (64-93)
Negative 4 20
TA/MA/OA Positive 20 6 83% (64-93) 75% (55-88)
Negative 4 18
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kappa of 0.55 (CI95%: 0.32-0.78), which is considered moderate
agreement.
Association of symptoms and FDG-PET/CT assessment
Table 4 shows a cross-tabulation of the presence of cranial symp-
toms and the results of the visual and semiquantitative FDG-PET/CT
assessments. 90% of patients presenting with cranial symptoms had a
positive (SUVmax  5.00) semiquantitative cranial artery assessment,
whereas all patients presenting without cranial symptoms showed a
negative (SUVmax < 5.00) semiquantitative cranial artery assess-
ment. Two patients presenting without cranial symptoms had posi-
tive visual assessment of the cranial arteries.
There was a positive correlation between the number of cranial
symptoms and the highest measured SUVmax in the cranial arteries
(r=0.4179, p=0.0421). Additionally, a higher number of cranialsymptoms was associated with a higher SUVmax in the VA (r=0.5492,
p=0.0054) (Fig. 4).
None of the individual cranial symptoms were associated with
increased uptake in any of the cranial arterial regions. Moreover,
there was no correlation between the number of cranial symptoms
and the number of affected arteries.
Association of Duplex Ultrasound and FDG-PET/CT assessment
Fisher’s exact test revealed no significant results in cross tabula-
tions of the visual and quantitative assessments with Duplex US
result (Table 5).
Discussion
The current study is the first to investigate the diagnostic accuracy
of FDG-PET/CT in biopsy proven C-GCA patients using both visual and
Fig. 3. Above: ROC curve of the highest (MAX) SUVmax and SUVmax SCV ratio (highest
measured SUVmax in all cranial arteries divided by SUVmax of blood pool in superior
caval vein). AUC values were calculated as 0.88 and 0.84 respectively. A SUVmax cut-
off value of 5.0 resulted in a sensitivity of 79% and a specificity of 92% (p<0.0001).
Below: ROC curve of the highest measured SUVmax values in all cranial arteries (MAX
SUVmax), and in the temporal artery (TA), maxillary artery (MA), vertebral artery (VA),
and occipital artery (OA) separately. AUC values were calculated as 0.88 for MAX SUV-
max, and 0.70 (TA), 0.80 (MA), 0.85 (VA), and 0.61 (OA).
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SUVmax cut-off value of 5.00 resulted in a 79% sensitivity and a 92%
specificity for C-GCA. Visual assessment showed a notably lower 75%Table 3
Cross tabulation of the results of the semiquantitative
Cranial Artery: SUVmax5.00 GCA Cont
TA/MA/VA/OA Positive 19 2
Negative 5 22
TA Positive 11 0
Negative 13 24
MA Positive 7 0
Negative 17 24
VA Positive 17 1
Negative 7 23
OA Positive 3 1
Negative 21 23
MA/VA/OA Positive 17 2
Negative 7 22
TA/MA/VA Positive 19 1
Negative 5 23
TA/MA/OA Positive 13 1
Negative 11 23
SUVmax5.00 was considered positive and SUVmax
cranial arteries, combinations of cranial arteries, and s
artery; MA, maxillary artery; VA, vertebral artery; OA,specificity, underlining the importance of objective measurements.
The presence of high intensity FDG uptake (visual score = 2)
improved specificity to 96%%and involvement of multiple arterial
regions improved specificity to 100%. Additionally, increased SUVmax
in the cranial arteries was associated with the presence of cranial
symptoms. These results show that FDG-PET/CT can be used to diag-
nose C-GCA. Due to especially the excellent obtained specificity in
both this and other studies, FDG-PET/CT may provide a valuable alter-
native to TAB [13, 14].
Until recently, FDG-PET/CT was considered unsuitable for the
detection of cranial artery inflammation, yet desirable in order to
expand the range of diagnostic tools [8,11,12]. Higher resolution
scanners employing time-of-flight (TOF) imaging may be the reason
for improved detectability [17]. The sensitivity of the visual and semi-
quantitative assessments was comparable with previous studies on
visual assessment of the cranial arteries on FDG-PET/CT. The 75%
specificity found on visual assessment in this study is notable lower
than in other FDG-PET/CT studies [13,14]. This may be due to differ-
ences in PET reconstruction and the use of one instead of multiple
trained observers in this study. Because of low visibility and complex
anatomical locations of the scored arteries, specifically training the
observers to assess the cranial arteries is likely to improve sensitivity
and specificity.
Whereas visual assessment used a more global interpretation of
the FDG-PET/CT image, semiquantitative assessment was based
solely on uptake intensity (SUVmax) in the cranial arteries. Both pre-
viously mentioned studies of FDG-PET/CT in C-GCA mentioned that
highest accuracy can be attained when using global interpretation
[13,14]. Although global interpretation is instrumental for diagnosis,
this study affirms that the use of standardised objective methods of
measurement and interpretation cannot be dismissed. Especially the
superior specificity found when using SUVmax measurements pro-
vides a rationale to increase the use of subjective FDG-PET assess-
ment methods. This standardisation is equally important to ensure
quality and reproducibility. Additionally, because the assessment
methods showed only moderate agreement, combining global inter-
pretation and SUVmax measurements may improve diagnostic accu-
racy even further [18].
This study also included specific data on the assessment of the TA,
MA, VA, and OA. Although this study exclusively included TAB posi-
tive cases, visual and semiquantitative PET assessments revealed pos-
itivity for the biopsied TA in only 58% and 38% of cases, respectively.
This indicates a difference between histopathological (TAB) andassessment of the cranial arteries.
rol Sensitivity (CI95%) Specificity (CI95%)
79% (60-91) 92% (74-99)
46% (28-65) 100% (86-100)
29% (15-49) 100% (86-100)
71% (51-85) 96% (80-100)
13% (4-31) 96% (80-100)
71% (51-85) 92% (74-99)
79% (60-91) 96% (80-100)
54% (35-72) 96% (80-100)
<5.00 negative. Results for bilaterally assessed
ensitivity and specificity are shown. TA, temporal
occipital artery; CI95%, 95% confidence interval.
Table 4
Cross tabulation of the FDG-PET/CT assessments and presence of cranial symptoms. Semiquantitative (SUVmax) and visual assessments
are shown separately.
*SUVmax  5.00 (positive) *SUVmax < 5.00 (negative) **Visually positive **Visually negative
Cranial symptoms present 19 2 18 3
Cranial symptoms absent 0 3 2 1
Total 19 5 20 4
*Highest SUVmax of the TA/MA/VA/OA
**TA/MA/VA/OA assessed.
ig. 4. Plot of the number of cranial symptoms on the x-axis and the SUVmax in the
ertebral artery (VA) on the y-axis. Spearman’s rho concluded a positive correlation,
0.5492, p=0.0054.
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v
r=Table 5
Cross tabulation of the result of the Duplex ultrasound (US) result and FDG-PET/CT assessment of the cranial arteries. Semiquan-
titative (SUVmax) and visual assessments are shown separately.
*SUVmax  5,0 (positive) *SUVmax < 5,0 (negative) **Visually positive **Visually negative
Duplex US positive 7 2 7 2
Duplex US negative 5 1 5 1
*Highest SUVmax of the TA/MA/VA/OA;
**TA/MA/VA/OA assessed.metabolic (FDG-PET) signs of vasculitis. This is in agreement with the
study by Nielsen et al., who found that in their TAB positive patient
group, only 51% had positive TA on FDG-PET/CT [13].
Although much is known about the involvement of the TA,
involvement of the VA is less well documented. This study found
high diagnostic accuracy for C-GCA when solely using semiquan-
titative assessment of the VA (AUC = 0.85). This is also reflected
in the study by Nielsen et al., where the most frequently affected
artery was the VA [13]. Several US studies show frequent involve-
ment of the VA in C-GCA. Occlusion of the VA can cause severe
neurological manifestations [19,20]. A correlation between the
number of reported cranial symptoms and the FDG uptake in the
VA in this study further highlights the importance of assessment
of these arteries.
Since recent years, clinicians increasingly rely on US as a diagnos-
tic tool for C-GCA. Results from a large study on US for diagnosing C-
GCA showed a 54% sensitivity and 81% specificity. The diagnostic
accuracy of US is highly dependent on the examiner’s skill, whereas
in FDG-PET/CT cranial artery assessment likely requires less addi-
tional training [13,14]. Additionally, FDG-PET/CT imaging is generally
used next to US already to diagnose LV-GCA. Results from this study
suggest that cranial artery assessment on FDG-PET/CT provides an
alternative to US, by attaining better diagnostic accuracy, showing
involvement of additional cranial arteries, and decreasing the num-
ber of diagnostic tests needed. Moreover, as presented in Table 5,FDG-PET/CT may provide additional value because, like TAB, US and
FDG-PET of the cranial arteries may visualise different signs of
inflammation.
This study has some limitations. The retrospective nature and
data collection of the study are prone to bias and error. The C-
GCA group included three patients with serum glucose levels
exceeding 7 mmol/L, which may have lowered vascular FDG
uptake in these patients and therefore have understated the
results. Additionally, it is worth noting that because TAB is the
only diagnostic method to definitively prove C-GCA, inflammation
in other arteries than the TA could not be histologically validated.
Including TAB negative C-GCA patients fell outside the scope of
this study because a negative TAB does not exclude C-GCA. More-
over, some included patients underwent TAB before FDG-PET/CT,
which can result in increased uptake at the location of this surgi-
cal procedure. However, of the 4 out of 5 patients in this study
who had TAB performed before FDG-PET/CT, multiple arteries
were assessed as positive, both on visual and semiquantitativeassessment. Regarding semiquantitative assessment, comparing
SUVmax between different arteries as performed in this study is
complicated because the TA and VA inherently show higher SUVs,
also in the control group. Despite these inherent differences, the
diagnostic accuracy combining all arteries was superior to that of
individual arteries, signifying that GCA patients can have compa-
rably high SUVmax along all four arteries. Lastly, results from this
study may not be generalisable to centres with less expertise in
vascular assessment on FDG-PET/CT. However, assessment in this
study was in line with previous work, which concluded high
interobserver agreement after only short training [13].
In conclusion, this study further strengthens the evidence that
FDG-PET/CT can be used along the entire spectrum of GCA, diagnosing
isolated C-GCA in addition to concurrent and isolated LV-GCA. Expand-
ing the use of FDG-PET/CT to the cranial arteries increases diagnostic
accuracy for C-GCA and its high specificitymaymake it a suitable alter-
native to TAB. Additionally, the diagnostic performance of semiquanti-
tative assessment provides a rationale to increase the clinical use of
standardised objective methods in the diagnosis of vasculitis.
Declaration of competing interest
Dr. E. Brouwer, as an employee of the UMCG, received speaker
fees and consulting fees from Roche in 2017 and 2018, which were
paid to the UMCG. The other authors declare no conflicts of interest.
P.H. Nienhuis et al. / Seminars in Arthritis and Rheumatism 50 (2020) 616623 623References
[1] Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern
in cranial and large-vessel giant cell arteritis. Arthritis Rheum [Internet] 1999
Feb;42(2):311–7 Available from https://www.ncbi.nlm.nih.gov/pubmed/
10025926.
[2] Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant
cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.
Rheumatol (United Kingdom) 2017;56(4):506–15.
[3] Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk
factors for visual loss in an Italian population-based cohort of patients with giant
cell arteritis. Arthritis Care Res 2005;53(2):293–7.
[4] Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A,
Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of
240 patients. Medicine (Baltimore) 2005;84(5):269–76.
[5] Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL. Large-
vessel giant cell arteritis: a cohort study. Rheumatol (United Kingdom) 2015;54
(3):463–70.
[6] Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al.The role of
ultrasound compared to biopsy of temporal arteries in the diagnosis and treat-
ment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness
study. 2016;
[7] Bowling K, Rait J, Atkinson J, Srinivas G. Temporal artery biopsy in the diagnosis of
giant cell arteritis: does the end justify the means? Ann Med Surg [Internet]
2017;20:1–5 Available from http://dx.doi.org/10.1016/j.amsu.2017.06.020.
[8] Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D. EULAR recom-
mendations for the use of imaging in large vessel vasculitis in clinical practice.
Ann Rheum Dis [Internet] 2018 Jan;77(5):636–43 Available from http://dx.doi.
org/10.1136/annrheumdis-2017-212649.
[9] Duftner C, Dejaco C, Sepriano A, Falzon L, Schmidt WA, Ramiro S. Imaging in diag-
nosis, outcome prediction and monitoring of large vessel vasculitis: a systematic
literature review and meta-analysis informing the EULAR recommendations.
RMD Open 2018;4(1).
[10] Belhocine T, Blockmans D, Hustinx R, Vandevivere J, Mortelmans L. Imaging of large
vessel vasculitis with18FDG PET: Illusion or reality? A critical review of the litera-
ture data. Eur J Nucl Med Mol Imaging [Internet] 2003 Sep 1;30(9):1305–13 [cited
2018 Nov 1]Available from http://link.springer.com/10.1007/s00259-003-1209-y.
[11] Slart RHJAJA, Slart RHJAJA, Glaudemans AWJM, Chareonthaitawee P, Treglia G,
Besson FL. FDG-PET/CT (A) imaging in large vessel vasculitis and polymyalgiarheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET
Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging
2018;45(7):1–20.
[12] Brodmann M, Lipp RW, Passath A, Seinost G, Pabst E, Pilger E. The role of 2-
18F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagno-
sis of giant cell arteritis of the temporal arteries. Rheumatology 2004;43
(2):241–2.
[13] Nielsen BD, Hansen IT, Kramer S, Haraldsen A, Hjorthaug K, Bogsrud TV. Simple
dichotomous assessment of cranial artery inflammation by conventional 18F-FDG
PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control
study. Eur J Nucl Med Mol Imaging [Internet] 2019 Jan 31;46(1):184–93 Available
from http://link.springer.com/10.1007/s00259-018-4106-0.
[14] Sammel AM, Hsiao E, Schembri G, Nguyen K, Brewer J, Schrieber L. Diagnostic
accuracy of PET/CT scan of the head, neck and chest for giant cell arteritis: the
double-blinded giant cell arteritis and pET scan (GAPS) study. Arthritis Rheumatol
[Internet] 2019;0(ja) Available from https://onlinelibrary.wiley.com/doi/abs/
10.1002/art.40864.
[15] Nielsen BD, Gormsen LC, Hansen IT, Keller KK, Therkildsen P, Hauge EM. Three
days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG
uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic
accuracy. Eur J Nucl Med Mol Imaging 2018;45(7):1119–28.
[16] Boellaard R, Delgado-Bolton R, Oyen WJGG, Giammarile F, Tatsch K, Eschner W.
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J
Nucl Med Mol Imaging [Internet] 2015 Feb;42(2):328–54 Available from https://
www.narcis.nl/publication/RecordID/oai:pure.rug.nl:publications%2F4415bf76-
0b8c-4942-9d06-8d2882e025ba.
[17] Surti S. Update on time-of-flight PET imaging. J Nucl Med 2015;56(1):98–105.
[18] Puppo C, Massollo M, Paparo F, Camellino D, Piccardo A, Shoushtari Zadeh Naseri
M. Giant cell arteritis: a systematic review of the qualitative and semiquantitative
methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission
tomography. Biomed Res Int 2014 2014.
[19] Pego-Reigosa R, Garcia-Porrua C, Pi~neiro A, Dierssen T, Llorca J, Gonzalez-Gay MA.
Predictors of cerebrovascular accidents in giant cell arteritis in a defined popula-
tion. Clin Exp Rheumatol [Internet] 2004;22(June 2014):13–7 Available from
http://www.embase.com/search/results?
subaction=viewrecord&from=export&id=L615860939.
[20] Richard S, Anxionnat R, Delaunay C, Ducrocq X. Giant cell arteritis revealed by
vertebrobasilar insufficiency. J Rheumatol [Internet] 2009 Feb;36(2):457–8 Avail-
able from http://www.jrheum.org/lookup/doi/10.3899/jrheum.080922.
